BIOTECHNOLOGY INDUSTRY
|
|
- Judith Manning
- 6 years ago
- Views:
Transcription
1 Long-term Prospects of the BIOTECHNOLOGY INDUSTRY Byung-Hwan Hyeon, Ph.D. The Present Situation of the Biotechnology Industry A. Definition and Scope The OECD defines biotechnology as activities that apply scientific logic and technologies to organisms, parts or part of an organism, products, and product-related models in the process of modifying living organisms or non-living things with the aim of producing knowledge, goods, and services (OECD data, 2004). Further, the scope of the bio-industry, or the biotechnology industry, according to the OECD criteria, is classified into medicine, agriculture/livestock and farming/fisheries, the environment, and energy markets. In particular, in the case of the medicine market, products derived from both biotechnologies and medical and chemical technologies account for 90% of the total market; the medicine market in the biotechnology industry is understood to include small-molecule compounded medicines. B. Biotechnology Industries and Their World Market Size The biotechnology industries are expected to cover a wide range of areas, ranging from the burgeoning medicine industry, solutions to food problems in the area of agriculture, livestock and fisheries, the development of technologies for tackling environmental problems such as environmental rehabilitation and waste treatment, the development of bio-energy to replace dwindling petroleum energy, to bioelectronics and others. This report focuses on the medicine industry which has the greatest addedvalue and is the acme of the biotechnology industry by describing its market trends, latest technological developments, and future prospects. The worldwide biotechnology industry accounted for US$540 billion in 2004, and has been estimated at US$600 billion for 2005 and as much as US$1 trillion for The medicine market accounts for 90% of the total biotechnology market Table 1. The medicine market, representing over 90% of the biotechnology industry, saw massive sales of major medicines last year alone as shown in Table APBN Vol. 10 No
2 Table 1. Biotechnology Industry and Its Estimated Market Size. Bio-industries Major products Current stage Market size for 2010 Major (US$100 million) participatory corporations Medicine Cholesterol lowering Commercialized 9,700 Pfizer, GSK, Amgen, drugs, Genetech erythrocyte growth accelerators Biotechnology Cell therapy, Basic principles 562 Aastrom, ONYX, drugs gene therapy, have been Vical transfusion drugs discovered, and applied research is underway. U-Health Bio chips, Applied 300 Affymetrics, operational systems technologies Medtronics accumulated Living modified Crops, animals, fish Commercialized 150 Monsanto, Syngenta organisms Biotechnology Image-based Commercialized 850 HP, GE, Agilent equipment diagnostic equipment, analyzers Biotechnological Microbial Initial 160 Shell, BP applications in decomposition, commercialization environment and biotechnological stage energy fuels Biotechnological Replacing existing Initial 250 Cargill, BASF, processes processes commercialization DuPont stage Source: Samsung Economic Research Institute reports, IMS health, Jain PharmaBiotech Report 2005, etc. APBN Vol. 10 No
3 Table 2. Worldwide Sales of Major Medicines (2004). Product Name Sellers Sales Applications Marketing (USD 100 million) Year Lipitor Pfizer Lowering cholesterol 1996 Zorcor Merck 52.0 Lowering cholesterol 1991 Seretide GlaxoSmithKline 45.0 Asthma treatment 1998 Norvasc Pfizer 44.6 Hypertension treatment 1992 Zyprexa Eli Lilly 44.2 Schizophrenia 1996 Nexium AstraZeneca 38.8 Gastric ulcer treatment 2000 Procrit/Eprex Johnson & Johnson 36.0 Anemia treatment 1990 Zoloft Pfizer 33.6 Depression treatment 1991 Effexor Wyeth 33.5 Depression treatment 1993 Plavix Bristol Myers Squibb 33.3 Thrombus resolvent 1997 Celebrex Pfizer 33.0 Arthritis treatment 1998 Fosamax Merck 31.6 Osteoporosis treatment 1995 Epogen Amgen 26.0 Anemia treatment 1989 Aranesp Amgen 24.7 Anemia treatment 2001 Enbrel Amgen 19.0 Arthritis treatment 1998 Neulasta Amgen 17.4 Anti-cancer supplementary 2002 Rituxan Genetech 17.1 Anti-cancer drug 1997 Viagra Pfizer 16.8 Impotence treatment 1998 Actos Takeda 16.9 Diabetes treatment 1999 Gleevec/Glivec Novartis 16.3 Anti-cancer drug 2001 Source: Top 400 prescription drugs (Med Ad News, 2005) C. Trends in Biotechnology R&D and Technologies The biotechnology industry, led by the United States, Great Britain, Japan, and Germany, is witnessing fierce competition between the different corporations. The six leading nations have invested 88% of the world s total R&D costs in this sector, and the 20 leading corporations, most of which are situated in the United States, represent 60% of the total market. Multinational pharmaceutical companies based in the United States are increasingly stepping up investment in R&D; in 2004, they invested a massive USD 38 billion, greater than the U.S. National Institute of Health s total R&D investment of about USD 28 billion. However, compared with the ever-increasing investment in R&D, these companies come up with a smaller number of products that successfully undergo novel drug development and commercialization, and thus, to ensure efficient R&D, form alliances with biotechnology ventures to increase investment in securing pipelines. Table 3 shows the top ten domestic and foreign pharmaceutical companies as of 2004 in terms of R&D costs compared with sales. The focal social issue most closely related to the development of the bioindustries concerns the completion of the human genome project, and its direct and rapidly projected benefits will be channeled into the medicine industry. Although the medicine market as of 2005 exceeded the already massive USD 500 billion, the era that follows the genome project will see an unfathomably large figure. Thus, research into new medicines for the treatment of diseases and enhancing the quality of life by exploiting the outcome of the human genome project could well become the area that creates the largest economic value of the 21st century. 936 APBN Vol. 10 No
4 Table 3. Top 10 Domestic and Foreign Companies (R&D Investment Ratio). Ranking Domestic Foreign Ranking Company name Investment Ratio (%) Company name Investment Ratio (%) (million won) (USD 1 million ) 1 LG Life Sciences 52, Eli Lilly 2, Hanmi 26, AstrZeneca 3, Yuyu, Inc. 3, Aventis 3, Boryung, Inc. 4, Sanofi-synthelabo 1, Daewoong Pharm. 19, Pfizer 7, Kun Wha 3, Novartis 3, Yuhan Corporation 19, F Hoffman-Ra 3, Bukwang Pharm. 5, Merck 3, Ildong 9, Wyeth 2, Daewon Pharm. 1, GlaxoSmithKline 4, Average 7.2% 15.6% Source: Parliamentary probe data on Korea Health Industry Institute, 2005 Prospects of the Biotechnology Industries A. Overview In the medicine market, which represents over 90% of the biotechnology market, the market for anti-cancer drugs, antibiotics and other existing drugs is important, but the market for novel drugs aimed at improving life quality for treating ageing, stress, obesity, and Alzheimer s disease, and bolstering memorization ability, is likely to be even more crucial. For instance, novel drugs such as Sanofi Aventis, the soon-to-be-marketed obesity treatment drug, Acomplia, and Pfizer s and Neurocrine Biosciences sleeping pill, Indiplon will each generate an annual turnover of US$6 billion at their expected peak. This achievement was made possible by the development of cutting-edge biotechnologies through research into geonomics and protein structure and function. Given the necessity for such state-of-the-art biotechnologies, the diversity of human desires, and the ageing of society, efforts are underway to discover drugs that will improve life quality and fulfill the ultimate human goal of pursuing a healthy, happy life. APBN Vol. 10 No
5 In the 21st biotechnology age, people can pursue lifestyles focused on staying young and healthy rather than concentrating on securing foods and survival, as was the case in the past. Furthermore, since obesity, stress, and other symptoms are closely related to Alzheimer s disease, diabetes, cancers, and various other diseases, these symptoms, if not cured, will inevitably lead to serious life threats. In the 21st century, these symptoms are being categorized along with serious diseases, and advanced pharmaceuticals companies, having understood this, are positively striving to discover novel drugs aimed at improving peoples life quality and enriching their lives. Biotechnology industries, as the state s primary growth engine, should find the best strategies to discover world-class new products and enter advanced markets. In the novel drug industry with the highest added value, it is the venture firms in biotechnologies rather than the existing pharmaceutical companies and large corporations that are currently are taking on bold challenges. Likewise, Korea s biotechnology industries are developing by fostering venture firms in biotechnologies and thus discovering world-class novel drugs. In response to such efforts, the government, for its part, has left open the door to the tech-heavy KOSDAQ stock market (like the U.S. NASDAQ) to the venture firms in technologies which have yet to boost their profitability, thus injecting huge private funds into the venture firms on top of the government s limited budgets for research and helping them evolve into world-class biotechnologies venture firms. So, ten years from now, Korea s biotechnology industries will become the nation s effective growth engine for the future. B. Appearance of Asian Corporations The United States is leading the world s biotechnology industries, while Asia, Korea, India, China, Japan and Singapore are rallying their national forces behind the development of the biotechnology industries. The Ernst & Young 2005 report forecast that Korea, Singapore, Sweden, and others have selected the biotechnology industries as their respective growth engine, have been intensively investing in these areas from a long-term perspective, and have created good research environments; as such, it is thought that they may outstrip the United States in this field. Dr. Byung-Hwan Hyeon Director, Biotech Policy Research Center Address: Korea Research Institute of Bioscience and Biotechnology Daejeon , Korea bhhyun@kribb.re.kr Furthermore, in the case of novel drugs, Korea and China joined the ranks of nations developing novel drugs in 2003 and 2004 respectively. In the case of Korea, the country is relatively less costly, and has the superior research manpower and technologies required to compete with nations whose multinational pharmaceutical companies are at the stage of discovering candidates for novel drugs that can secure intellectual property rights. Likewise, Korea boasts superior manpower in the biotechnologies, particularly in the fields of medicine and chemical and structural biology, as well as cutting-edge infrastructure facilities secured through the Ministry of Science and Technology s huge investment in the G7, such as light accelerators, high magnetic-field nuclear-magnetic resonators, and super computers, and is the tenth nation to obtain FDA approval for its novel drug. By taking advantage of these strengths, if Korea intensively invests in the development of novel drugs, it will be able to boost national wealth not only through its semiconductor industry and IT industries, but also through its biotechnology industries, and thereby enter the ranks of the G7 nations in the 21st century. 938 APBN Vol. 10 No
Biotechnology Industry and its Prospects Jay Kim
Biotechnology Industry and its Prospects Jay Kim Senior Managing Director M-Venture Investment www.m-vc.co.kr 1. Biotechnology 2. Biotechnology industry - classification - major markets - bio drug / Genentech
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationGenerics: The Ripple Effect
S A L ES & M A R K E TI NG I N SIGHTS Generics: The Ripple Effect Judith Kulich Introduction When a pharmaceutical patent expires and generic competition moves in, the branded product s market share erodes
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGeneral issues. Rational Drug Design lecture 1
Rational Drug Design lecture 1 Łukasz Berlicki General issues E-mail: lukasz.berlicki@pwr.edu.pl consultations: room 322a/A2, Monday, Thursday, 11-12 AM TEST, January 22 nd, 3.15PM Additional tests: 25.01-12.02
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationInvisible Advantage: How Intangibles Are Driving Business Performance. Jonathan Low Federal Reserve Bank of New York.
Invisible Advantage: How Intangibles Are Driving Business Performance Jonathan Low Federal Reserve Bank of New York July 11, 2002 2002 Cap Gemini Ernst & Young 1 The markets are valuing your intangibles
More informationBIOPHARMACEUTICAL BUSINESSES
BIOPHARMACEUTICAL BUSINESSES Our Biopharmaceuticals businesses consist of four patientcentric, customer-facing business units. The business units are responsible for further clinical development and lifecycle
More informationComments Submitted to the Federal Trade Commission on. the Pfizer-Wyeth and Merck- Schering Plough Mergers
Comments Submitted to the Federal Trade Commission on the Pfizer-Wyeth and Merck- Schering Plough Mergers William S. Comanor and F. M. Scherer University of California Santa Barbara and Los Angeles Harvard
More informationAnalysis of Lebanon s Pharmaceutical Market
November 2013 Analysis of Lebanon s Pharmaceutical Market (2009 2013) Table of Contents: World Pharmaceutical Market:... 2 Lebanon s Pharmaceutical Market:... 5 Pharmaceutical Imports and Exports:... 7
More informationGlobal and China Biopharmaceutical Industry Report, 2010
Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound
More informationBIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW
BIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW The study reviews, analyzes and projects the global market for Biopharmaceuticals for the period 2006 2015 PUBLISHED: APRIL 2010 Report Code: BT001 Pages: 240
More informationThe Drug Industry: Pharmaceuticals and Biopharmaceuticals
The Drug Industry: Pharmaceuticals and Biopharmaceuticals Presenter Prof. Geoffrey Poitras Simon Fraser University Vancouver, BC Thursday, March 27, 2014 Disclosure Prof. Poitras is a professor of Finance
More informationQuo vadis Medical Industry?
Quo vadis Medical Industry? 18th December 2014 Karl Branzén Sweden has experienced the winds of change in the drug industry In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and
More informationPharma IP Evergreening Strategies (i.e., Patent Extension) Using Nanotechnology
Pharma IP Evergreening Strategies (i.e., Patent Extension) Using Nanotechnology Jeffrey H. Rosedale, Ph.D Registered U.S. Patent Attorney Partner, Woodcock Washburn LLP, Philadelphia, Pennsylvania Legal
More informationGovernment Perspective on the Life Sciences
Government Perspective on the Life Sciences Dr Chong-Chou Lee, Ph.D. Director, Science & Technology Advisory Group, Executive Yuan, Taipei, Taiwan Introduction Enormous advances and product innovations
More informationThe Drug Industry: Pharmaceuticals and Biopharmaceuticals
The Drug Industry: Pharmaceuticals and Biopharmaceuticals Presenter Prof. Geoffrey Poitras Simon Fraser University Vancouver, BC Thursday, Jan. 15, 2015 Disclosure Prof. Poitras is a professor of Finance
More informationIntroduction of HANDOK Pharmaceuticals
Introduction of HANDOK Pharmaceuticals Overview Respecting Humanity, Corporate Morality, Serving Community Since its foundation in 1954, HANDOK, has unwaveringly pursued its goals of corporate development
More informationMerck: Refocusing Research and Development
Merck: Refocusing Research and Development April 25, 2003 Ji Chong Helane Crowell Stacy Kend Prepared for: Merck & Co Table of Contents Executive Summary.................................... 02 Financials
More informationDISRUPTIVE INNOVATIONS AND GLOBAL NETWORKS: THE CASE OF GENOMICS AND PHARMACEUTICAL INDUSTRY APRIL 2014
DISRUPTIVE INNOVATIONS AND GLOBAL NETWORKS: THE CASE OF GENOMICS AND PHARMACEUTICAL INDUSTRY MARÍA A. POZAS CENTER FOR SOCIOLOGICAL STUDIES EL COLEGIO DE MEXICO APRIL 2014 The sequencing of the entire
More informationMolecular Biotechnology. Principles and applications of recombinant DNA
Molecular Biotechnology Principles and applications of recombinant DNA Chapter 1. The Molecular Biotechnology Revolution Science and Technology Science Search for knowledge Technology Practical of knowledge
More informationPharmaceutical Industries
Taiwan Biotech and the Pharmaceutical Industries Chei-Hsiang Chen, Ph.D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan The government has a
More informationIndustry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
Global Biomanufacturing Trends, Capacity and Technology Drivers Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationQuo vadis Medical Industry?
Quo vadis Medical Industry? 17th December 2015 Karl Branzén Sweden has experienced the winds of change in the drug industry u In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and
More informationVISION & STRATEGY FIC LIC. Interview with the President
VISION & STRATEGY Interview with the President A conversation with Isao Teshirogi, President and CEO about the Shionogi Growth Strategy 2020 (SGS2020) VISION & STRATEGY SGS2020 Growth Strategies Under
More informationA European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
More informationCALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY
CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY Executive Summary Prepared for Applied Biological Technologies Initiative Economic and Workforce Development Program California
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More informationGLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS
GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS BIO009G January 2017 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-417-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationSept High-Tech Industry Investment Promotion Team
Sept. 9. High-Tech Industry Investment Promotion Team Government Policy Semiconductor s No. market share in DRAM, SRAM, LDII and NANO.% share of the global market Exports exceeded US$9billion Automobile
More informationCurrent Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V
Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products
More informationGlobal Biomanufacturing Trends, Capacity, and Technology Drivers: Industry Biomanufacturing Capacity Overview
BIOPHARM PROCESSING» Global Biomanufacturing Trends, Capacity, and Technology Drivers: Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant Dawn M. Ecker Consultant BioProcess Technology
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION) Feedback from 147 Nordic patient groups PUBLISHED JUNE 2016 Syöpälääkkeiden kehitys on ollut hyvä, ja yhä useammat paranevat.
More information2010/SOM3/LSIF/002. Opening Remarks. Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA)
010/SOM/LSIF/00 Opening Remarks Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA) Life Sciences Innovation Forum Sendai, Japan 18-19 September 010 Message From JPMA President APEC Life
More informationLehman Brothers Global Healthcare Conference
Lehman Brothers Global Healthcare Conference Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer March 20, 2007 Safe Harbor Except for the historical information contained herein, this
More informationFunding neglected disease R&D The next hurdle
Funding neglected disease R&D The next hurdle An international campaign to enhance access to medicine in the developing world by discovering and developing new treatments for neglected diseases is beginning
More informationThe overview of Estonian biotechnology sector (2012)
The overview of Estonian biotechnology sector (2012) Olavi Otepalu 15.06.2012, Tallinn Bioeconomy in the Baltics. Inspiration conference. Defining the biotechnology sector Always necessary prior to specify
More informationPart I: Life Sciences Overview
Part I: Life Sciences Overview Biotechnology Introduction The Drug Development Process Genomics/Proteomics Agricultural Biotechnology Pharmaceuticals Market Size & Current Status Major Opportunities Major
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationPHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationPromotion and Development Collaborations Between Established Players
Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com
More informationKEYWORDS: Outsourcing; innovation; lean; drug; research; discovery
CHEMSITRY TODAY Vol 31(4) P. 14-17 / CROS/CMOS Strategic outsourcing of pharmaceutical R&D - Bringing pharma and drug discovery into the information age KEVIN LUSTIG Assay Depot, Inc Corresponding Author
More informationEvaluate Data Kit Pharma, Biotech and Medtech, May 2018
Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Contents Introduction 2 Sourcing Instructions / About Evaluate 3 Section 1 Pharma Industry Overview Top 15 Rx and OTC Sales 4 WW Rx and OTC Sales
More informationPharmaceutical Manufacturing and Process Analytical Technology
Pharmaceutical Manufacturing and Process Analytical Technology Trevor Murphy IMAR Technology Gateway Institute of Technology Tralee Tralee, Ireland Trevor.Murphy@research.ittralee.ie Abstract - Global
More informationMarkets. Pharmaceutical Industry Water Business Trends
Markets Pharmaceutical Industry Water Business Trends T he technology and markets for high-purity water for use in pharmaceutical applications are dynamic. There are continuous technology improvements
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationComparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June
More informationThe Changing Landscape of Mammalian Cell Culture Manufacturing Capacity
The Changing Landscape of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual bioprocessuk Conference Nov 30-Dec 1 2011 Glasgow, Scotland BioProcess Technology Consultants
More informationADDING VALUE TO A PRODUCT S LIFE CYCLE MANAGEMENT: Product Enhancement Through Drug Delivery Systems
ADDING VALUE TO A PRODUCT S LIFE CYCLE MANAGEMENT: Product Enhancement Through Drug Delivery Systems Anand Baichwal, Ph.D. Sr. VP of Research & New Technology Development, and Chief Scientific Officer
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationGlobal Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity
Global Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual BioProcess International Europe 2012 Apr 18-19 Prague, Czech Republic BioProcess Technology
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationThe Pharmaceutical Industry: An Industry Note
CASE The Pharmaceutical Industry: An Industry Note 1 The pharmaceutical industry consisted of all enterprises that were involved in the invention of drugs, production of the active substances in drugs,
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS PUBLISHED OCTOBER 2016 [Question to respondents: Which companies have the best record
More informationBIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationPatients are Counting on Us: It s Time to Act
Patients are Counting on Us: It s Time to Act Brian Johnson Chairman Rx-360 Senior Director Supply Chain Security Pfizer, Inc. 24 th Global GS1 Healthcare Conference October 2, 2013 THE WALL STREET JOURNAL
More informationUNLEASHING MEDICAL AFFAIRS
UNLEASHING MEDICAL AFFAIRS DEC 2017 UNLEASHING MEDICAL AFFAIRS Sweeping changes across the pharmaceutical industry have heightened the expectations for Medical Affairs and have created an unprecedented
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationBuilding Biotech Technology Transfer Opportunities
For a clearer market perspective Building Biotech Technology Transfer Opportunities Sponsor and developer strategies for success Report Price Publication date 1995/ 2885/$3835 March 2010 H E A L T H C
More informationISPUB.COM. Opportunities for Generic Drugs in India. P Sharma, S Kumar, R Pahwa, A Sharma INTRODUCTION BRANDED DRUG GENERIC DRUG
ISPUB.COM The Internet Journal of Third World Medicine Volume 8 Number 1 P Sharma, S Kumar, R Pahwa, A Sharma Citation P Sharma, S Kumar, R Pahwa, A Sharma.. The Internet Journal of Third World Medicine.
More informationTAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare.
TAIWAN Where innovations are shaping a new era of intelligent healthcare World-class medical centers and hospitals Over 1800 biotech companies Best healthcare system in the world Top-ranked life science
More informationProtein research and bioinformatics
Protein research and bioinformatics LauritzenConsulting Content and application Proteins are the fundamental building blocks of life. Research in Greater Copenhagen focuses on the significance of proteins
More informationNastech Pharmaceutical Company Inc. Company Presentation
Nastech Pharmaceutical Company Inc. Company Presentation 2005 Nastech Forward-Looking Statements Statements made in this presentation may be forward-looking statements within the meaning of Federal Securities
More informationf r o m o u r p i p e l i n e t o y o u r b o t t o m l i n e
TTO Circle f r o m o u r p i p e l i n e t o y o u r b o t t o m l i n e Amir Naiberg, CEO From Our Pipeline to Your Bottom Line The Weizmann Institute of Science Discovering Basic Science Yeda R&D Co.
More informationHIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS
HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN 10 POINTS 1 67 BILLION IN REVENUES The biotech-medtech industry accounted for around 330,000 direct and indirect jobs and 67 billion in sales in 2016
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationAn Economic Analysis of Generic Drug Usage in the U.S.
September 2011 $931 Billion SAVINGS An Economic Analysis of Generic Drug Usage in the U.S. EXECUTIVE SUMMARY As government leaders in Washington and across the country look for ways to cut health care
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationMedical breakthroughs have always driven our business
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationParameters of Development - Drug Delivery Enabled/Enhanced Products (DDEP ) A Review (Chapter 7)
CHAPTER 7 FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product approvals by the FDA over the period 2000-2010. This is a simple analysis that provides
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationBuilding Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success
Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success Drug developers have long been under pressure to introduce new products in an environment of escalating
More informationLONG-TERM BENEFITS FROM RESEARCH INTO STREPTOMYCES BACTERIA
LONG-TERM BENEFITS FROM RESEARCH INTO STREPTOMYCES BACTERIA Many of the most important antibiotics used in hospitals around the world come from Streptomyces bacteria. Recent discoveries have shown that
More informationFrance Pharma RepTrak 2017
France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1 Why Measure Reputation? The success of your company
More informationWINNING BRAND VS. GENERIC COMPETITION
WINNING BRAND VS. GENERIC COMPETITION - Competition 2.0: Brands vs. Generics - Winning Beyond the Molecule www.bernardassociatesllc.com Innovator and generic companies are colliding as they invade each
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationCTS East Coast. Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization. Connect with us to connect with Asia
Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization Connect with us to connect with Asia CTS East Coast Oct 19 th, 2011 Philadelphia Introduction Zuellig Pharma Asia Pacific
More informationCellular Assays. A Strategic Market Analysis. Sample Slides
A Strategic Market Analysis Sample Slides 2002 For information contact: Frontline Strategic Consulting, Inc. 1065 E. Hillsdale Blvd, Suite 403, Foster City, CA 94404 650-525-1500 x125, x135 or x145 info@frontlinesmc.com
More informationMultiple Sclerosis Treatment Market Research Report - Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/940 Multiple Sclerosis Treatment Market Research Report - Global Forecast till 2023 Report / Search Code: MRFR/HC/0434-HCRR
More informationPharmaceutical Innovation at a Crossroads
Pharmaceutical Innovation at a Crossroads The New Face of Pharma R&D Kenneth I Kaitin, Ph.D. Director and Research Professor Tufts Center for the Study of Drug Development Global Clinical Supply Group
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationTrends, Issues, Forecasts
Trends, Issues, Forecasts PRESENTED BY Doug Long Vice President, Industry Relations Copyright 2004, IMS Health. No portion of this document may be reproduced, used or distributed in any form without written
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationResearch & Reviews: Journal of Hospital and Clinical Pharmacy
Research & Reviews: Journal of Hospital and Clinical Pharmacy Challenges Faced by MNCs in Pakistan Due to Unethical Practice of National Pharmaceuticals Industry Yasir Mehmood * Faculty of Pharmacy University
More informationInvest in Canada BIOPHARMACEUTICALS. Canada s competitive advantages
211 Invest in Canada BIOPHARMACEUTICALS Canada s competitive advantages MAJOR GLOBAL INVESTORS IN canada Amgen AstraZeneca Bayer Bristol-Myers Squibb GlaxoSmithKline Johnson & Johnson Jubilant Life Sciences
More informationAMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA
News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone (805) 447-1000 Fax (805) 499-3507 www.amgen.com AMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION
More informationMarketspace. Keywords: early-stage collaboration, licensing, lead optimisation, lead identification, target validation, drug discovery
Mark J. Belsey spent his PhD looking at the role of cell signalling pathways underlying cell cycle progression in oncology. He is now working for the Competitive Intelligence healthcare team with Datamonitor,
More informationBusiness and Industry Advisory Committee to the OECD - Comité Consultatif Economique et Industriel Auprès de l OCDE
Business and Industry Advisory Committee to the OECD - Comité Consultatif Economique et Industriel Auprès de l OCDE In Committee BIOTECHNOLOGY: A KEY CONTRIBUTOR TO SUSTAINABLE ECONOMIC GROWTH A Vision
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More information